Nilotinib and Ritonavir interaction

Nilotinib and Ritonavir: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.

Major

Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.

What the FDA labels say

From the Ritonavir (Norvir) label · effective 2026-07-23

Major

Anticancer Agents: abemaciclib, apalutamide, dasatinib, encorafenib, ibrutinib, ivosidenib, neratinib, nilotinib, venetoclax, vinblastine, vincristine ↑ anticancer agents ↓ ritonavir # Apalutamide is contraindicated due to potential for loss of virologic response and possible resistance to NORVIR or to the class of protease inhibitors [see Contraindications (…

Drug interactionsnames NilotinibView label on DailyMed
Moderate

A decrease in the dosage or an adjustment of the dosing interval of nilotinib and dasatinib may be necessary for patients requiring co-administration with strong CYP3A inhibitors such as NORVIR.

Drug interactionsnames NilotinibView label on DailyMed
Minor

Please refer to the nilotinib and dasatinib prescribing information for dosing instructions.

Drug interactionsnames NilotinibView label on DailyMed

From the Nilotinib (CAVHANZA) label · effective 2026-08-07

Major

Avoid use of concomitant drugs known to prolong the QT interval and strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 , 7.2 )] .

Boxed warningby drug classView label on DailyMed
Major

Avoid use of concomitant drugs known to prolong the QT interval and strong CYP3A4 inhibitors.

Boxed warningby drug classView label on DailyMed
Major

Therefore, avoid concomitant CAVHANZA use with strong CYP3A4 inhibitors and/or medicinal products with a known potential to prolong QT [see Dosage and Administration ( 2.9 ), Drug Interactions ( 7.1 , 7.2 )] .

Warnings and precautionsby drug classView label on DailyMed
Major

Strong CYP3A Inhibitors: Avoid concomitant use with CAVHANZA or reduce CAVHANZA dose if concomitant use cannot be avoided.

Drug interactionsby drug classView label on DailyMed
Major

Strong CYP3A Inducers: Avoid concomitant use with CAVHANZA.

Drug interactionsby drug classView label on DailyMed

Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.

Open in the checker

Not medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.